To evaluate the influence of baseline biochemical parameters on the improvement in best corrected visual acuity (BCVA) and reduction in central foveal thickness (CFT) in patients treated with intravitreal bevacizumab (IVB; Avastin, Genentech, Inc) for macular edema (ME) secondary to central retinal vein occlusion (CRVO).
A mong the retinal vascular diseases, central retinal vein occlusion (CRVO) is considered one of the most important causes of ocular morbidity and visual disability as it is preceded in incidence only by diabetic retinopathy (DR) and branch retinal vein occlusion (BRVO). 1 The prevalence of CRVO has been reported in landmark studies to be between 0.08% and 0.5%. [2] [3] [4] Wellestablished risk factors include systemic conditions like elevated blood pressure (BP), diabetes mellitus (DM), hyperlipidemia, hypercoagulable states, abnormal or altered clotting factor profiles, elevated serum homocysteine levels, hyperviscoscity syndromes including antiphospholipid antibody syndrome, systemic connective tissue disorders, and inflammatory conditions. [5] [6] [7] There are also studies on the effect of hemorheological factors, clotting factors, lipoprotein (a), serum lipids, and homocysteine on vascular occlusions. 6, 8, 9 Clinical manifestations of CRVO are strikingly distinct and the most important cause of visual impairment is macular edema (ME). 10 Macular edema in CRVO is a poor responder and requires multiple interventions to achieve anatomic resolution. The treatment modalities currently in use for ME in CRVO are injection of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and intravitreal steroids. 11 Predictive factors for improved anatomic and visual outcomes after treatment for CRVO have been analyzed in previous studies. 12 Younger age at presentation, better best corrected visual acuity (BCVA), early treatment, and lesser central retinal thickness (CRT) have been associated with better outcomes after treatment for CRVO. 13 Though the risk factors for the onset of CRVO in a particular individual are well known, the direct influence of these systemic parameters on resolution of ME, the most important retinal pathology responsible for visual impairment, remains unclear. On the other hand, extensive work has been carried out on the influence of hematologic factors on DR and diabetic macular edema (DME). [14] [15] [16] We speculated that, in CRVO, the response of ME to treatment and in turn, the improvement in BCVA, may be related to the baseline systemic and biochemical factors responsible for the onset of CRVO. The aim of this study was to assess the influence of systemic and biochemical factors on visual and optical coherence tomography (OCT) outcomes after intravitreal bevacizumab in CRVO.
MATERIALS AND METHODS
The Aravind Eye Hospital institutional review board and institute ethics committee clearance was obtained. The study was conducted in accordance with the tenets of the Declaration of Helsinki and its amendments.
Participants
Patients who presented to our institute with CRVO in either eye in the period of January 2015 to June 2015 were identified and case records reviewed. The diagnosis of CRVO was established clinically and the presence and extent of macular edema was documented on OCT. Those who underwent at least 1 standard dose of intravitreal injection of bevacizumab (Avastin, Genentech, Inc) and those who had a follow-up visit 1 month after the last injection were included in the study. A dose of 1.25 mg bevacizumab/0.05 mL is used in our institute for intravitreal therapy. Those patients who did not receive intravitreal bevacizumab (IVB) injections and those who did not have the first month follow-up after the last injection were excluded from the study. Similarly, eyes with other vascular occlusions, ME due to other causes, and previously treated CRVO were not considered for the study. After exclusion, 70 patients with unilateral CRVO were found to satisfy the criteria required and were included in the study.
Clinical Assessment
The case records of all 70 patients were reviewed along with imaging reports and reports of biochemical parameters. Details of presentation, medical and ophthalmic history, and complete ocular examination were noted. Trained technicians performed refraction on all patients and BCVA for distance was noted using the illuminated Snellen chart (Aurochart 1.1.4, Aurolab, Madurai, India). Corresponding logarithm of the minimum angle of resolution (logMAR) values were calculated and used for statistical analysis. Intraocular pressure was noted using the Topcon CT 80 noncontact tonometer (Topcon Medical Systems, Inc, Oakland, NJ) by trained personnel. Every patient had undergone comprehensive ophthalmic evaluation including anterior segment examination and gonioscopy with slit lamp, posterior segment examination by noncontact fundus biomicroscopy using 90 diopter (D) lens, and indirect ophthalmoscopy using 20 D lens by an ophthalmologist. Clinically, CRVO was identified with the presence of superficial and deep retinal hemorrhages in a flameshaped pattern in all retinal quadrants, dilated and tortuous retinal blood vessels in all quadrants, macular thickening or frank cystoid edema, optic disc edema, or hyperemia along with the possible presence of cotton wool spots on the retina. Care was also taken to identify the presence of relative afferent pupillary defect (RAPD) that is an indicator of ischemic or nonischemic CRVO and neovascularization at the optic disc, over the iris, or in the anterior chamber angle. Every patient had macular OCT at each visit. Patients also had hematologic investigations done at the first visit and they were documented for the study. Biochemical investigations done at the first visit were hemoglobin (Hb) by the cyanmethemoglobin method, fasting blood sugar (FBS) and postprandial blood sugar (PPBS) by the glucose oxidase-phenol aminophenazone enzymatic method, blood urea (BU) by the urease glutamate dehydrogenase method, serum creatinine (SC) by the Jaffe test, total cholesterol (TC) by the cholesterol oxidase-phenol aminophenazone enzymatic method, serum triglycerides (ST) by the colorimetric enzymatic method, high density lipoprotein (HDL) and low density lipoprotein (LDL) by the homogenous method, very low density lipoprotein (VLDL) and TC/HDL ratio by the manual method, and glycosylated hemoglobin (HbA1C) by the turbidimetric inhibition immunoassay. 
RAPD Present, n (%)
7 (21) 5 (14) 5 (19) 2 (10) 2 (9) 3 (20) 2 (14) 2 (14) 2 (15) 4 (20) 1 (10) 3 (25) 1 (6) 2 (20) 2 (25) 4 (17) 2 (13) 3 (14) 3 (17) 2 (13) 3 (30) 5 (19) 3 (16) 6 (21) 2 (12) 3 (10) 5 (28) 4 (24) 4 (11) 7 (24) 4 (11) 7 (24) 3 (9) 8 (28) 3 (9) 5 (25) 7 (29) 4 (10) 1 (8) Based on the clinical and OCT parameters, on confirmation of the presence of ME (intraretinal fluid and cystic spaces) and/ or subretinal fluid, IVB was given. Using standard injection protocols and employing aseptic techniques, 1.25 mg/0.05 mL IVB was given 3 to 3.5 mm away from the limbus in the superotemporal or interotemporal quadrant. The patients were reviewed after a month and underwent complete reevaluation. At reexamination the need for the next injection was again decided on an as-needed basis based on clinical and OCT parameters.
Subgrouping of Dependent and Independent Variables
Each independent variable (ie, demographic, systemic, and biochemical parameter) was further divided into subgroups. Subgrouping was done based on standard accepted normal, borderline, and abnormal levels for the particular parameter under consideration. The presence of RAPD and the number of injections in each subgroup were first analyzed to look for baseline differences between the subgroups. The outcome variables [improvement in BCVA and reduction in central foveal thickness (CFT)] were then divided into 2 groups. Improvement of BCVA by at least 2 Snellen lines was separated from those eyes that had less than 2 Snellen lines of improvement. Decrease of CFT by at least 500 µm was differentiated from those eyes with less than 500 µm reduction in CFT.
Macular Spectral Domain OCT
Optical coherence tomography scans were obtained using the Cirrus HD-OCT 500 (Carl Zeiss Meditec, Dublin, CA) spectral domain OCT system. The central foveal thickness used for analysis was measured as the distance from the internal limiting membrane to the inner margin of the retinal pigment epithelial layer. A single clinician did the measurements.
Statistical Analysis
Statistical analysis was performed with SPSS 23 (SPSS Inc, Chicago, IL). Demographic, systemic, and hematologic parameters of the study population were tabulated using descriptive statistics. The general change in BCVA and CFT before and after treatment was compared using paired t test. Each independent variable was correlated against difference in BCVA (in logMAR) and difference in CFT (in µm) to look for association. Categorical dependent variables were assessed with χ 2 test and continuous variables were assessed with independent samples test (Mann-Whitney U test). Binary logistic regression was then performed to understand the relationship between variables by altering the dependent variables as improvement in BCVA by 2 or more Snellen lines (yes/no) and reduction of CFT by 500 µm or more (yes/no). A statistical significance was computed when the P value was less than 0.05. Wald χ 2 and odds ratio (OR) were deduced. Table 1 shows the demographic and baseline systemic parameters in the study group. Seventy patients with established CRVO in a single eye were enrolled in the study. There were more males than females (45/25). The right eye was more often affected than the left (38/32). Patients presented with symptom duration in the range of 1 day to 3 years with a mean of 3 months. On average, 2.3 injections of intravitreal bevacizumab were given (range, 1 to 7 injections). The BCVA at presentation and at final follow-up (1 month after the last IVB) was noted in Snellen notation. Corresponding logMAR values were used for statistical analysis.
RESULTS

Demographic Profile
Subgroups were divided as shown in Table 2 . The various subgroups of each systemic parameter being analyzed were comparable with respect to the number of IVB received and presence of RAPD (Tables 2, 3 , and 4). Initial BCVA was comparable between subgroups except for FBS categories (0.81 ± 0.70, 1.15 ± 0.75, 1 ± 0.99; P = 0.03). After treatment BCVA revealed a difference between BU (0.57 ± 0.5, 0.92 ± 0.92; P = 0.04) and SC (0.39 ± 0.38, 0.90 ± 0.86; P = 0.02) subgroups alone. All other parameters had comparable final BCVA across subgroups. Similar analysis of initial and final CFT did not show any statistical difference between the subgroups of any systemic parameter.
There was no statistical difference in the overall BCVA before and after treatment. However, there was a significant decrease in overall CFT after treatment (P < 0.05; Fig. 1 ). The improvement in BCVA (in logMAR) noted at the final visit for each eye was plotted against the decrease in CFT for the same eye (Fig. 2) .
Significant association was noted between improvement in BCVA and the following parameters: BU [Pearson coefficient (r) = 0.389, P = 0.017], SC (r = 0.412, P = 0.01), and TC/HDL ratio (r = −0.300, P = 0.026; Table 5 ). Similar analysis for improvement in CFT showed a significant correlation with initial CFT (r = 0.636, P < 0.01). A B 
Biochemical Parameters in CRVO With ME
Analysis of Demographic and Systemic Variables
Among the demographic and systemic variables studied, the odds of achieving a 2 or more Snellen line improvement in BCVA was noted in patients who were less than 60 years of age (OR, 2.18), those who had a diastolic blood pressure (DBP) of less than 79 mm Hg (OR, 2.05), DBP 80 to 89 mm Hg (OR, 3.30), and those who were not diabetic (OR, 2.15) or had the disease for less than 5 years (OR, 2.10). Similarly, the odds of having a 500 µm or greater drop in CFT was noted in patients who had symptoms for less than 1 month, systolic blood pressure (SBP) of less than 120 mm Hg, and less than 5-year duration of diabetes and hypertension (Table 3, Fig. 3 ). We also noted no significant difference between subgroups with respect to improvement in BCVA or drop in CFT.
Analysis of Biochemical Parameters
When the same analysis was carried out for biochemical parameters, a significant difference in BCVA improvement between the subgroups was noted only in patients who had normal and elevated BU [P = 0.04; OR, 8.46; 95% confidence interval (CI), 0.90 to 102.20] and SC (P < 0.01; OR, 12.77; 95% CI, 1.73 to 94.27) values (Table 4 , Fig. 4) . Although there was no significant difference in change of BCVA, OR was greater than 2 for HbA1c less than or equal to 6.4% (OR, 3.73). The odds of having a decrease of CFT by more than 500 µm was more than 2 in patients who had FBS less than 100 mg% (OR, 2.11), FBS 101 to 124 mg% (OR, 2.66), VLDL less than 30 mg% (OR, 2.89), and HbA1C less than 6.4% (OR, 3.04). However, no statistical significance was found.
DISCUSSION
The systemic risk factors, clinical features, natural course of the disease, and treatment modalities for CRVO have been extensively studied. 15, 17 Among the many pathologic changes in the retina, ME remains the single most important cause of decrease in BCVA. Research has shown that anti-VEGF agents are the treatment of choice for ME secondary to CRVO. 12,13 A 2-line improvement in BCVA on the Snellen chart is often used as a measure of treatment outcome with anti-VEGF agents.
Systemic factors such as the age of the patient, duration of the ocular symptoms, baseline BCVA, CFT, and previous treatment status have been used to predict the outcome of treatment for ME. Factors such as younger age, shorter duration of the disease, better initial BCVA, and CFT predict better visual outcomes with treatment. 13 In another study, older age was noted to be a factor associated with better visual outcomes. 18 Metabolic syndrome (hypertension, hypercholesterolemia, and hypertriglyceridemia) is one of the most commonly implicated systemic disorders related to the onset of CRVO. 19 Besides these common disorders, other clinical risk factors that have an association with the occurrence of CRVO are history of cerebrovascular accidents or even a family history of the same. 7, 20, 21 Altered levels of basic blood investigations like hematocrit, hemoglobin, lipids, glucose, blood urea nitrogen, and serum creatinine are associated with increased incidence of CRVO. 8, 19 Dodson et al 22 were among the first to show that lipid levels in the blood are related to the onset of CRVO. They highlighted the association between hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia with CRVO. 22 Thereafter, lipoprotein (a), fibrinogen, and plasma homocysteine levels 
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were found to be elevated in patients with CRVO. 6 The presence of antibodies such as antiphospholipid antibody and anticardiolipin antibody (ACA) are known to have increased incidence of CRVO, with ACA being more dominant in the scenario of CRVO in younger age groups. 23 Central retinal vein occlusion tends to occur more commonly in patients with factor V Leiden, other thrombophilias, and hyperviscosity syndromes. Sofi et al 24 have identified susceptibility to CRVO by analyzing the hemorheological profile of patients. Variables such as whole blood viscosity, erythrocyte deformation index, and plasma viscosity were analyzed and found to be significantly different in patients with CRVO and healthy subjects. 24 Although various risk factors like hypertension, diabetes mellitus, hyperlipidemia, blood urea, serum creatinine, and other hematological parameters have been implicated in the onset of CRVO, not much is known about their actual influence on the macula during the course of the disease and its treatment. In contrast to ME in CRVO, the influence of systemic factors on DME has been the subject of discussion in various studies.
14,15 Although 1 study showed that neither baseline systemic factors nor change of systemic control from baseline affected the visual outcome at month 24, another study did show that there was a significant difference in the response of macular edema when plasma glucose levels were well controlled. 14, 15 The perceived difference in the etiopathogenesis of ME in CRVO and DM may be the reason for the lacunae in studying the influence of systemic risk factors on the response of CRVO-associated ME to treatment. Diabetes mellitus is a metabolic disorder that is characterized by defects in plasma glucose metabolism caused by altered quantity or function of insulin. 25 Diabetic macular edema is a specific retinal manifestation of this defined pathologic entity. On the other hand, ME in CRVO is not directly related to any individual systemic condition. Although definite risk factors for the onset of CRVO This retrospective study was designed to study the impact of the baseline systemic and biochemical parameters on resolution of ME and improvement in BCVA. There was a significant decrease in CFT after treatment without a statistically significant improvement in BCVA. Thinning of the fovea and extravasation of fluid after anti-VEGF therapy, though beneficial in their own accord, do not reverse the detrimental anatomic changes in the outer retina and resultant functional deficiencies. Besides overall thinning of the macula, intact external limiting membrane, ellipsoid zone, and photoreceptor outer segments are necessary for functional visual gain. 26 Improvement in CFT was associated with initial CFT. Ach and colleagues 13 found a similar association in CRVO. Using a definition of at least 2 lines of improvement in Snellen acuity and at least 500 µm reduction in CFT as a desirable response to IVB therapy, among the systemic and biochemical parameters analyzed, the chances of better visual gain were noted in younger individuals, nondiabetics, those with less than 5-year duration of diabetes, those with DBP less than 89 mm Hg, normal renal parameters, and HbA1c less than 6.4%. Initial BCVA and other systemic or biochemical parameters were not associated with better visual gain. Better ME resolution with treatment was seen with individuals who had symptoms for less than 1 month, SBP less than 120 mm Hg, less than 5-year duration of diabetes and hypertension, FBS less than 124 mg%, VLDL less than 30 mg%, and HbA1c less than 6.4%. Apart from renal parameters, despite the statistical insignificance of other parameters in predicting better functional or anatomic outcomes, a higher OR can partly explain the chances of better BCVA and CFT in patients who have the said parameters in the normal range.
Blood urea and SC reflect renal function with a fair degree of accuracy. 27, 28 Neurologic functions are known to be adversely affected when renal function is deranged. 29, 30 Friedman and L'Esperance 31 described renal-retinal syndrome and retinal changes in patients with compromised kidney function in DM. Recently, elevated BU and SC were shown to be associated with decreased retinal nerve fiber layer thickness. 32, 33 It has been postulated that neurotoxicity precedes retinal microvascular damage in the presence of circulating toxins and excitotoxic metabolites in the setting of renal insufficiency. Of particular importance are oxidative stress and elevated nitric oxide levels in the blood stream, which catalyze endothelial and neuronal damage. Imbalance in the subtypes of nitric oxide synthases have been noted in cardiorenal syndromes. 34, 35 In our study, we have noted a significantly favorable outcome with respect to BCVA in patients with normal renal parameters. When extrapolated to the available evidence, it is implied that sound baseline renal function predicts better visual gain after treatment for ME in CRVO. The role of renal dysfunction-mediated functional neuronal damage is better understood when we consider that the decrease in CFT (anatomic improvement) was not statistically significant between the 2 subgroups of patients, whereas the gain in BCVA (functional improvement) was significantly better in patients who had normal renal parameters at baseline. Therefore, it stands to reason that normal renal parameters offer substantial advantage for visual gain over and above the proportion of visual gain that could be attributed to decrease in CFT alone.
The merit of this study lies in highlighting the association of systemic and biochemical parameters with improvement in BCVA and CFT after treatment for ME in CRVO that were hitherto not known. The study was not without limitations. As this was a retrospective study, there were missing data, which could have affected the statistical analysis. The BCVA and CFT at first month follow-up after intravitreal bevacizumab injections were taken into consideration for analysis. However, not all patients had the same number of injections. There was significant difference in BCVA among the FBS subgroups even at the start of the study. Therefore, the predictive value of FBS for improvement in BCVA cannot be estimated. The role of macular ischemia could not be completely elucidated in the absence of fluorescein angiograms that are not routinely done at baseline. In our study, we used the presence of RAPD as an indirect indicator of the presence of ischemia. Future studies in this direction could address these issues prospectively with more participants.
In conclusion, for ME in CRVO, IVB-related improvement of visual function is significantly better when renal parameters are under control and higher retinal thickness at baseline was associated with more reduction in CFT. Apart from these, younger age, shorter diabetes duration, normal or borderline DBP, and well-controlled HbA1c may partly explain better visual outcomes just as shorter symptom duration, shorter duration of diabetes and hypertension, normal SBP, normal or borderline FBS, normal VLDL, and well-controlled HbA1c are more often associated with better resolution of ME after treatment with IVB.
